Retina Biomarkers for Treatment Selection in DME

Epidemiology, disease burden, and current treatment options.

By Kailynn M. Barton, BS, Muhammad Abidi, BS, Rajiv M. Sastry, BA, et al.

AI Screening for Diabetic Retinopathy

Head-to-head validation studies and emerging equity metrics are refining how these systems are evaluated and deployed.

By Abraham Olvera-Barrios, MD, PhD, Cathy Egan, FRANZCO

New Strategies for Managing Diabetic Retinopathy

Advances in therapy and technology are extending durability and enabling individualized management of DR.

By Omar Saeed, DO, MPH, Veeral S. Sheth, MD, MBA, FACS

Steroid Strategies in Diabetic Macular Edema

Patient selection, dosing strategies, and practical considerations for incorporating corticosteroids into clinical practice.

By Ashish Sharma, MD, Baruch D. Kuppermann, MD, PhD

Telemedicine and Retina Care

Lessons in access, equity, and efficiency.

By Nnamdi Elem Okore, OD

Update on Diabetic Disease

Upfront: The May/June issue has a focus on diabetic retinal disease.

By Diana V. Do, MD

PRIMA Implant Shows Clinical Potential

Clinical Trial Download: Early PRIMAvera trial data suggest that subretinal photovoltaic implantation is a viable approach to restoring central vision in GA.

By Frank Brodie, MD, MBA, Nitish Mehta, MD, Yasha Modi, MD

Diabetes Mellitus Coding in Retina

Coding Q&A: Accurate ICD-10 coding for diabetic eye disease depends on clearly documenting diabetes type, retinopathy severity, macular edema status, and laterality.

By Elizabeth Cifers, MBA, MSW, CHC, CPC

Clinical Trial Update May/June 2026

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

A Potentially Synergistic Approach to Retinal Exudative Diseases

Vorolanib inhibits not only VEGF signaling but also blocks pro-inflammatory IL-6 signaling by uniquely binding JAK1.

By Julie Greenbaum, editor

Video: Preclinical Data Highlights Potential of VLTR-559 for Wet AMD

“We are really excited about these preclinical pharmacology results, and we believe VLTR-559 is on track to demonstrate superior durability with a reliable 6-month treatment protocol for patients with wet AMD,” Dr. Livia Brier said in her ARVO presentation. 

By Livia Brier, PhD

Video: Eliminating SHRM May Improve Visual Outcomes 

SriniVas Sadda, MD, FARVO, discusses his paper on subretinal hyperreflective material (SHRM), its relevance to vision, and findings from the TENAYA and LUCERNE studies. 

By SriniVas R. Sadda, MD, FARVO

Study Compares Near-Real Surgical Specimens to Cadaver Eyes

David Almeida, MD, MBA, PhD, discusses a study he presented on Near-Real Surgical Specimens, and evaluates its utility as a standardized model for quantifying suprachoroidal injection dynamics and biodistribution compared to traditional cadaveric models.

By DAVID R.P. ALMEIDA, MD, MBA, PHD

Video: Artificial Intelligence Dominates ARVO Retina Sessions

Nearly half of the retina program is related to artificial intelligence, according to ARVO program co-chair Amitha Domalpally, MD, PhD. Other areas of interest include real-world anti-VEGF data and regenerative medicine.

By Amitha Domalpally, MD, PhD

Imaging Leukocyte Dynamics in Retinal Disease

At ARVO 2026, Richard B. Rosen, MD, presented in vivo AOSLO imaging of leukocyte trafficking in retinal disease.

By Jim Gallagher, senior managing editor

NEI Director Highlights Opportunities for Vision Research

Michael F. Chiang, MD, discusses funding constraints and emerging NIH initiatives during his ARVO 2026 presentation.

By Jim Gallagher, senior managing editor

Inside Focus A-Eye’s Inaugural Meeting

Sharon Bakalash, MD, PhD, CBA, describes how the interdisciplinary pre-ARVO forum explored ways to move AI from concept to clinic.

By Sharon Bakalash, MD, PhD, CBA

DME AWARE Study Defines Key Needs

At ARVO 2026, Baruch D. Kuppermann, MD, PhD, reported expert consensus on unmet needs in DME management, including early intervention and noninvasive therapies.

By Jim Gallagher, senior managing editor

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.

By Katie Binley, PhD

IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial

The phase 2 Alluvium trial compares vamikibart to anti-VEGF therapy in treatment-naïve patients with center-involving DME.

By Arshad M. Khanani, MD, MA, FASRS

AI Streamlines GA Trial Screening, Study Finds

A clinic-based algorithm reduced screen failures and showed close agreement with manual measurements in data presented at ARVO 2026.

By Jim Gallagher, senior managing editor

Stem Cell Therapy Shows Early Vision Gains in GA

Early findings from a phase 1 study of Astellas’s ASP7317 suggest possible functional improvement following subretinal RPE cell transplantation in advanced geographic atrophy.

Racing Toward Efficient AI Workflows

At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.

By Devinder Chauhan, MD, FRCOphth, FRANZCO

Real-World Imaging Confirms Faricimab Response in DME

Six-month VOYAGER data presented at ARVO by Robert P. Finger, MD, PhD, demonstrate early, meaningful reductions in IRF and SRF.

FARETINA Study Confirms Faricimab Durability

An IRIS Registry analysis presented at ARVO 2026 shows stable vision, durability, and reduced treatment burden across more than 40,000 eyes over 2 years.

By Ferhina Ali, MD

Treatment Gaps Linked to Worse Long-Term Vision Outcomes in Wet AMD

At ARVO 2026, Andrew A. Moshfeghi, MD, MBA, FASRS, presented a retrospective analysis of the Vestrum Health database examining treatment interruptions in neovascular AMD.

By Andrew A. Moshfeghi, MD

Insights From the 2026 Cogan Award Lecture at ARVO

Cecilia S. Lee, MD, MS, and Aaron Y. Lee, MD, MSCI, discussed how large data sets and artificial intelligence are reshaping precision health and ophthalmic research.

By Cecilia S. Lee, MD, MS, Aaron Y. Lee, MD, MSCI

SOL-1 Analysis Highlights Longer Time to Rescue With Axpaxli

Phase 3 data support the durability profile of Axpaxli in patients with neovascular AMD.

By Patricio G. Schlottmann, MD

2026 Retina World Congress Preview

Baruch D. Kuppermann, MD, PhD, highlights the global focus and broad retina agenda of the upcoming Retina World Congress meeting in Fort Lauderdale.

By Baruch D. Kuppermann, MD, PhD

VOY-101 Targets GA Through Complement Regulation Biology

Safety data presented at ARVO 2026 supports continued development of a novel complement-modulating gene therapy that provides continuous protection for patients with geographic atrophy.

By Jim Gallagher, senior managing editor

Co-Management Strategies in GA Care: Recognizing Geographic Atrophy Earlier

GA care functions optimally when detection, referral, and treatment operate as one continuous system.

By Damon Dierker, OD, FAAO, Ankur M. Shah, MD, FASRS

Disrupting the Supply Chain With Quality and Quantity

Turbare combines rigorous quality standards, innovative compounding, and rapid production to support the medication supply needs of ophthalmologists and retina specialists.